2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-112319
    MK-8457 1312518-84-5 98%
    MK-8457 is a dual SYK/ZAP70 inhibitor. MK-8457 can be used for research of rheumatoid arthritis.
    MK-8457
  • HY-112363
    Aloisine A 496864-16-5 98%
    Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC50s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC50=0.5 μM) and GSK-3β (IC50=1.5 μM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research.
    Aloisine A
  • HY-112428
    Sirt2-IN-2 1862238-01-4 98%
    Sirt2-IN-2 (Compound 10) is a selective Sirt2 inhibitor with an IC50 of 0.118 μM.
    Sirt2-IN-2
  • HY-112446
    ST638 107761-24-0 98%
    ST638 is a potent tyrosine kinase inhibitor (IC50=370 nM). ST638 also targets the CSF-1 receptor and inhibits PGE2 production.
    ST638
  • HY-112455
    cFMS Receptor Inhibitor IV 959626-45-0 99.61%
    cFMS Receptor Inhibitor IV (Compound 42) is a potent cFMS inhibitor with an IC50 of 0.017 μM.
    cFMS Receptor Inhibitor IV
  • HY-112538
    1-(1-Naphthyl)piperazine hydrochloride 104113-71-5 98%
    1-1-Naphthylpiperazine hydrochloride (1-NP hydrochloride; 1-Naphthylpiperazine hydrochloride) is a serotonergic derivative of quipazine, which is both an agonist for 5-HT1A receptor and an antagonist for 5-HT2A receptor. 1-1-Naphthylpiperazine hydrochloride induces cell apoptosis. 1-1-Naphthylpiperazine hydrochloride prevents the immunosuppression and photocarcinogenesis.
    1-(1-Naphthyl)piperazine hydrochloride
  • HY-112549
    5-oxo-ETE 106154-18-1 98%
    5-oxo-ETE is a potent chemoattractant for eosinophils. 5-oxo-ETE inhibits selenium-induced apoptosis in prostate cancer cells. 5-oxo-ETE can be used in research into asthma, allergic diseases, cancer and cardiovascular disease.
    5-oxo-ETE
  • HY-112553
    HZ52 1077626-51-7 98%
    HZ52 is a potent, reversible 5-lipoxygenase inhibitor, blocking leukotriene synthesis with an IC50 of 0.7 μM in intact human polymorphonuclear leukocytes.
    HZ52
  • HY-112561
    Bis-PEG1-PFP ester 1807539-02-1
    Bis-PEG1-PFP ester is a non-cleavable (1 unit PEG) ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
    Bis-PEG1-PFP ester
  • HY-112575
    Tiazotic acid 64679-65-8
    Tiazotic acid is a metabolic agent that has immunomodulatory, anti-inflammatory, antioxidant, anti-ischemic, cardio- and endothelioprotective, antiplatelet, hepatoprotective activities. Tiazotic acid increases the levels of eNOS. Tiazotic acid also reduces the level of D-dimer in the blood, which reduces the risks of heart attacks and strokes in post-COVID syndrome.
    Tiazotic acid
  • HY-112621
    Leukotriene A4 methyl ester 73466-12-3 98%
    Leukotriene A4 methyl ester (LTA4 methyl ester) is synthesized in mast cells, eosinophils, and neutrophils from arachidonic acid by 5-lipoxygenase (5-LO), which exhibits both lipoxygenase and LTA4 synthase activities. LTA4 is rapidly metabolized by LTA4 hydrolase or LTC4 synthase to LTB4 or LTC4, respectively. LTA4, from leukocytes, is known to undergo transcellular metabolism in platelets, erythrocytes, and endothelial cells. Further metabolism of LTA4 by 15-LO leads to lipoxin biosynthesis. LTA4 as a free acid is highly unstable. The methyl ester is stable and can be readily hydrolyzed to the free acid as needed.
    Leukotriene A4 methyl ester
  • HY-112736
    RG 14893 141835-49-6 98%
    RG 14893 is a high affinity, competitive, orally active leukotriene B4 receptor antagonist.
    RG 14893
  • HY-112738
    AX048 873079-69-7 98%
    AX048 is an inhibitor for calcium-dependent phospholipase A2 cPLA2 with a XI(50) of 0.022 mole fraction and reveals an antihyperalgesic efficacy.
    AX048
  • HY-112739
    SC-41930 120072-59-5 98%
    SC-41930 is a orally active eukotriene-B4 receptor antagonist. SC-41930 alleviates inflammation in guinea pig acetic acid-induced colonic inflammation model.
    SC-41930
  • HY-112740
    SC-53228 153633-01-3 98%
    SC-53228 is an orally active human leukotriene B4 receptor (LTB4 receptor) antagonist. SC-53228 exerts its anti-inflammatory effect by specifically blocking the LTB4 receptor and inhibiting neutrophil infiltration. SC-53228 has demonstrated significant efficacy and good safety in various inflammatory models. SC-53228 can be used for a variety of inflammatory diseases, such as psoriasis and ulcerative colitis.
    SC-53228
  • HY-112742
    CP-195543 204981-48-6 98%
    CP-195543 is a potent, selective and orally active leukotriene B4 (LTB4) receptor antagonist with IC50s of 6.8, 37.0 nM for human neutrophils and murine spleen membranes, respectively. CP-195543 blocks CD11b up-regulation. CP-195543 inhibits LTB4-mediated neutrophil infiltration.
    CP-195543
  • HY-112828
    LEI105 1800327-36-9 98%
    LEI105 is a potent, highly selective and reversible dual diacylglycerol lipase (DAGL)-α/DAGL-β inhibitor. LEI105 reduces 2-arachidonoylglycerol levels in Neuro2A cells. LEI105 also reduces cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model. LEI105 is promising for research of diseases, such as obesity, related metabolic disorders and neuroinflammation.
    LEI105
  • HY-112864
    TGFβRI-IN-6 2072051-04-6 98%
    TGFβRI-IN-6 (compound 22) is a potent TGFβRI inhibitor with an IC50 value of 0.55 nM. TGFβRI-IN-6 has the potential to enhance anti-tumor immunity.
    TGFβRI-IN-6
  • HY-112885
    nor-NOHA 189302-40-7 98%
    nor-NOHA is a selective and reversible arginase inhibitor. nor-NOHA induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA has anti-leukemic activity. nor-NOHA can used in study of endothelial dysfunction, immunosuppression and metabolism.
    nor-NOHA
  • HY-112894
    ZG-10 1408077-04-2 98%
    ZG-10 (JNK-IN-2) is a JNK inhibitor, with IC50 values of 809 nM, 1140 nM and 709 nM for JNK1, JNK2, and JNK3, respectively. ZG-10 (JNK-IN-2) is a potential anti-SARS-CoV-2 agent.
    ZG-10
Cat. No. Product Name / Synonyms Application Reactivity